Functions, Markers, and mIHC Detection Protocols for 7 Core Cell Types in the Tumor Microenvironment
Many people's understanding of tumors is limited to "a cluster of rapidly proliferating cancer cells." But in fact, tumors are never the solo battle of a single cell type — they are complex ecosystems with intricate structures, diverse cells, and constant interactions, known as the tumor microenvironment (TME). The growth, invasion, and metastasis of tumors, as well as the efficacy or resistance to immunotherapy, are not determined by tumor cells alone, but by the interactions of dozens of cell types within the microenvironment.
To truly understand tumors and optimize tumor research and treatment, the first step is to recognize the core cellular components of the tumor microenvironment. This is precisely why multiplex immunohistochemistry (mIHC) technology has become the core tool for tumor research.
To truly understand tumors and optimize tumor research and treatment, the first step is to recognize the core cellular components of the tumor microenvironment. This is precisely why multiplex immunohistochemistry (mIHC) technology has become the core tool for tumor research.
I. Decoding the Tumor Microenvironment: Beyond Cancer Cells, Six Core Cell Types Each Play Their Roles
A complete tumor tissue is not composed of a single tumor cell type, but a complex ecosystem consisting of tumor cells, immune cells, stromal cells, vascular cells, and extracellular matrix (ECM), collectively known as the tumor microenvironment (TME). These cells continuously communicate through cytokines, chemokines, growth factors, and metabolic signals, collectively influencing tumor initiation, invasion, metastasis, and immunotherapy response.
1. Tumor Cells: The Core Driver of Disease Progression
Tumor cells are the core component of the tumor microenvironment and the primary force driving tumor initiation, development, and metastasis. In addition to possessing continuous proliferation, invasion, and migration capabilities, tumor cells can actively reshape their surrounding microenvironment. Through secretion of various cytokines and growth factors such as TGF-β, IL-10, and VEGF, they promote angiogenesis, recruit immunosuppressive cells, and reduce immune cell killing capacity through expression of immune checkpoint molecules like PD-L1, thereby achieving immune escape. Therefore, tumor cells are not only the main target of immune system attack but also important regulators of the entire tumor ecosystem.
2. Cancer-Associated Fibroblasts (CAFs): Important Regulators Shaping the Tumor Stroma
Cancer-associated fibroblasts (CAFs) are among the most abundant stromal cells in the tumor interstitium, playing important roles in the formation and maintenance of the tumor microenvironment. Stimulated by signals released from tumor cells, normal fibroblasts can be activated to form CAFs, producing large amounts of extracellular matrix components including collagen, fibronectin, and matrix metalloproteinases, which alter tissue structure and promote tumor cell invasion and migration. Additionally, CAFs secrete factors such as TGF-β, IL-6, and VEGF to promote tumor growth, angiogenesis, and immune suppression. They also form physical barriers that prevent T cells from entering the tumor region, creating an immune-excluded state in tumors, making them important factors influencing tumor progression and immunotherapy response.
3. Tumor-Associated Macrophages (TAMs): Key Cells Linking Inflammation and Immune Escape
Tumor-associated macrophages (TAMs) are a numerically abundant and functionally complex immune cell population in the tumor microenvironment, playing important roles in tumor progression, immune regulation, and treatment response. Based on functional states, macrophages are typically classified as M1 type with anti-tumor inflammatory effects and M2 type promoting tumor development, while TAMs in most solid tumors typically exhibit M2-like characteristics. TAMs promote angiogenesis through secretion of VEGF, inhibit T cell activity through expression of molecules like PD-L1 and ARG1, and release matrix metalloproteinases to promote tumor cell invasion and metastasis. Therefore, TAMs are considered important regulatory hubs connecting chronic inflammation, immune suppression, and malignant tumor development.
4. T Cells: Core Executors of Anti-Tumor Immunity
T cells are important immune forces that recognize and eliminate tumor cells. CD8⁺ cytotoxic T cells are the main anti-tumor effector cells, capable of directly killing tumor cells through release of perforin and granzymes. CD4⁺ helper T cells regulate immune responses through secretion of cytokines, while regulatory T cells (Treg) suppress effector T cell function through release of immunosuppressive factors like IL-10 and TGF-β, helping tumors achieve immune escape. However, under prolonged tumor antigen stimulation, CD8⁺ T cells are prone to functional exhaustion, characterized by elevated inhibitory receptors such as PD-1 and decreased killing capacity. Therefore, analyzing the quantity, activity, and spatial distribution of different T cell subsets is an important basis for evaluating tumor immune status and immunotherapy efficacy.
5. Dendritic Cells (DCs): The Bridge Connecting Innate and Adaptive Immunity
Dendritic cells (DCs) are among the most important antigen-presenting cells in the body, playing a central role in initiating anti-tumor immune responses. Under normal circumstances, DCs can capture tumor antigens and activate T cells through antigen presentation, triggering immune attacks against tumor cells. However, in the tumor microenvironment, affected by immunosuppressive factors, some DCs exhibit functional dysfunction, characterized by decreased antigen presentation capacity and insufficient T cell activation, thereby promoting immune tolerance. Therefore, the quantity, maturation status, and functional changes of DCs are important factors influencing tumor immune surveillance and immunotherapy efficacy.
6. Tumor-Associated Neutrophils (TANs): Important Immune Cells Regulating Inflammation and Metastasis
In recent years, the role of tumor-associated neutrophils (TANs) in tumor development has received increasing attention. Based on different functional states, TANs can exhibit anti-tumor or pro-tumor effects. Some N2-type TANs promote invasion and metastasis by releasing inflammatory factors, promoting angiogenesis, and secreting proteases that help tumor cells break through tissue barriers. Additionally, TANs can regulate the local immune environment, affecting T cell activity and immunotherapy efficacy. Therefore, neutrophils are not merely participants in inflammation but important immune regulatory members in the tumor microenvironment.
7. Endothelial Cells: Key Factors Controlling Tumor Angiogenesis and Metastasis
Endothelial cells are important components of blood vessels, playing key roles in tumor growth and metastasis. As tumors rapidly proliferate and require abundant oxygen and nutrient supply, tumor cells release angiogenesis factors such as VEGF and FGF, stimulating endothelial cells to form new blood vessels. However, tumor neovascularization typically has abnormal structure, disordered arrangement, and low functionality, not only affecting drug delivery but also hindering effective immune cell infiltration into tumor regions, creating an immunosuppressive environment. Therefore, the state of tumor blood vessels not only determines tumor nutrient supply and metastatic capacity but also directly affects immunotherapy efficacy.
Summary of Core Cell Types in the Tumor Microenvironment
| Cell Type | Main Functions | Representative Markers |
|---|---|---|
| Tumor Cells | Proliferation, invasion, immune escape | CK, EpCAM, PD-L1 |
| CAF | Stromal remodeling, immune barrier | α-SMA, FAP, COL1A1 |
| TAM | Immune suppression, pro-angiogenesis | CD68, CD163, CD206 |
| CD8⁺ T Cells | Tumor killing | CD3, CD8, Granzyme B |
| Treg | Immune suppression | CD3, CD4, FOXP3 |
| DC | Antigen presentation | CD11c, HLA-DR |
| TAN | Inflammation regulation, metastasis | CD66b, MPO |
| Endothelial Cells | Angiogenesis | CD31, CD34 |
For tumor spatial research, the spatial distribution and interactions between tumor cells, immune cells, and stromal cells are key to understanding tumor progression mechanisms and immunotherapy responses. Therefore, in multiplex immunofluorescence (mIF/TSA) studies of the tumor immune microenvironment, researchers typically construct multi-marker detection panels for comprehensive analysis of different cell populations and functional states. For example, using CK to mark tumor regions, distinguishing tumor cells from surrounding tissue; detecting T cell infiltration through CD3/CD8 to evaluate anti-tumor immune activity; analyzing the distribution and immune regulatory status of tumor-associated macrophages using CD68/CD163; identifying immunosuppressive Treg cells using FOXP3; observing the spatial distribution of cancer-associated fibroblasts (CAFs) through markers like α-SMA and FAP; analyzing tumor vascular structure using CD31; and assessing immune escape status through immune checkpoint molecules such as PD-1/PD-L1. Through these multi-dimensional marker combination detections, researchers can simultaneously analyze "which cells are present," "where these cells are located," "how quantities change," and "how they interact with each other" within the tumor microenvironment on the same tissue section, thereby more comprehensively revealing tumor immune regulation mechanisms. This is also an important reason for the rapid development of spatial immunology and the widespread attention to TSA multiplex immunofluorescence technology in tumor research in recent years.
II. Fatal Shortcomings of Traditional IHC: Single-Marker Detection Misses the True Picture of Tumors
For a long time, immunohistochemistry (IHC) has been the conventional technology for pathological detection and tumor research. However, traditional single-color IHC has unavoidable technical limitations, making it difficult to adapt to the complex research needs of the tumor microenvironment.
The core pain point of traditional IHC is that only one cellular marker can be detected on a single tissue section. Simply put, a single tumor tissue section can only identify CD8⁺ T cells, or separately show Treg cells or TAM cells in one staining, and cannot simultaneously present all core cells on the same section.
This leads to multiple drawbacks in research and detection: First, it consumes large amounts of precious tumor tissue samples. Limited pathological sections are repeatedly split and stained multiple times, wasting sample resources significantly. Second, different sections have subtle differences in tissue location and cell distribution, making it impossible to accurately restore the spatial adjacency relationships and interaction patterns of various cell types. Third, only independent data of single cells can be obtained, making it impossible to analyze core mechanisms such as multi-cell coordinated regulation and immunosuppressive networks. The resulting tumor microenvironment information is fragmented and one-sided, difficult to support precise mechanism research and efficacy evaluation.
The core pain point of traditional IHC is that only one cellular marker can be detected on a single tissue section. Simply put, a single tumor tissue section can only identify CD8⁺ T cells, or separately show Treg cells or TAM cells in one staining, and cannot simultaneously present all core cells on the same section.
This leads to multiple drawbacks in research and detection: First, it consumes large amounts of precious tumor tissue samples. Limited pathological sections are repeatedly split and stained multiple times, wasting sample resources significantly. Second, different sections have subtle differences in tissue location and cell distribution, making it impossible to accurately restore the spatial adjacency relationships and interaction patterns of various cell types. Third, only independent data of single cells can be obtained, making it impossible to analyze core mechanisms such as multi-cell coordinated regulation and immunosuppressive networks. The resulting tumor microenvironment information is fragmented and one-sided, difficult to support precise mechanism research and efficacy evaluation.
III. mIHC Technology Breakthrough: One Section, Full Unlocking of the Tumor Microenvironment
Compared with the single detection limitation of traditional IHC, multiplex immunohistochemistry (mIHC) has achieved technological innovation in tumor microenvironment detection, perfectly adapting to the research needs of multi-cell, multi-marker, and spatial analysis.
The core advantage of mIHC lies in its reliance on TSA signal amplification technology, enabling simultaneous staining of multiple markers and co-localization analysis of multiple cells on the same tumor tissue section. Without repeated section preparation and multiple stainings, a single section can simultaneously and clearly distinguish tumor cells, CD8⁺ T cells, Treg cells, NK cells, CAFs, TAMs, and other cell types, accurately presenting the quantity ratio, expression intensity, spatial distribution, and interaction relationships of various cells.
Through mIHC technology, researchers can completely break free from the fragmented limitations of traditional detection, intuitively constructing a complete cellular atlas of the tumor microenvironment, accurately analyzing tumor immune activation and suppression mechanisms, and the microenvironmental supporting conditions for tumor proliferation and invasion. This provides comprehensive, precise, and three-dimensional experimental data for tumor mechanism research, target screening, immunotherapy efficacy prediction, and resistance mechanism analysis.
The core advantage of mIHC lies in its reliance on TSA signal amplification technology, enabling simultaneous staining of multiple markers and co-localization analysis of multiple cells on the same tumor tissue section. Without repeated section preparation and multiple stainings, a single section can simultaneously and clearly distinguish tumor cells, CD8⁺ T cells, Treg cells, NK cells, CAFs, TAMs, and other cell types, accurately presenting the quantity ratio, expression intensity, spatial distribution, and interaction relationships of various cells.
Through mIHC technology, researchers can completely break free from the fragmented limitations of traditional detection, intuitively constructing a complete cellular atlas of the tumor microenvironment, accurately analyzing tumor immune activation and suppression mechanisms, and the microenvironmental supporting conditions for tumor proliferation and invasion. This provides comprehensive, precise, and three-dimensional experimental data for tumor mechanism research, target screening, immunotherapy efficacy prediction, and resistance mechanism analysis.
IV. TSA-mIHC Kit: Empowering Precise Tumor Microenvironment Research Efficiently
To address the pain points of multi-cell detection in the tumor microenvironment, the TSA-mIHC kit has specifically achieved efficient implementation of simultaneous detection of multiple cells, providing a one-stop solution for tumor research with outstanding core value.
- Sample Utilization: Leveraging mature TSA tyramide signal amplification technology, the kit significantly improves detection sensitivity, enabling multi-marker detection on a single section, which greatly conserves precious clinical tumor tissue samples and perfectly adapts to research and clinical detection scenarios with scarce or limited samples.
- Data Value: Breaking through the information barrier of traditional single-marker detection, one experiment can obtain multi-cell, multi-dimensional, and spatialized microenvironment data, significantly improving experimental information volume and data completeness, avoiding experimental errors caused by section differences, making tumor microenvironment research more precise and efficient.
- Experimental Efficiency: The standardized kit operation process is simple and highly stable, requiring no complex experimental optimization. It can quickly achieve multiplex staining detection of batch samples, significantly shortening the experimental cycle, reducing research costs, and facilitating efficient advancement of tumor microenvironment mechanism research, drug development, and clinical efficacy evaluation.
Conclusion
The complexity of tumors is essentially the complexity of the tumor microenvironment. Single cell markers can no longer meet the needs of modern tumor research and precision medicine. From the "single-point observation" of traditional IHC to the "panoramic scanning" of mIHC, this is an important upgrade of tumor research from one-sided to comprehensive, from static to three-dimensional. EnkiLife TSA-mIHC kit focuses on spatial pathology and tumor microenvironment research scenarios, relying on mature and stable TSA signal amplification technology, adapting to various sample types including paraffin, frozen, and organoids, with advantages of high sensitivity, low background, and high compatibility. Combined with professional technical support, it helps researchers efficiently complete multi-cell co-localization detection and accurately analyze tumor microenvironment immune regulation networks. Only by unlocking the multi-cell panorama of the tumor microenvironment with EnkiLife's high-quality TSA-mIHC kit can we truly understand the mechanisms of tumor occurrence and development, laying a solid technical foundation for breakthroughs in tumor precision research and clinical diagnosis and treatment.